BlossomHill Therapeutics (BLSM) stock: insider trades, news & valuation
Strong buyingShare price and insider trades
BlossomHill Therapeutics insider trading at a glance (Oct 9, 2026): in the past 12 months, 6 insiders bought $25.2M and 0 sold $0 of BLSM stock on the open market, including a cluster buy that began Aug 7, 2026.
Get emailed when insiders cluster-buy stocks like BLSM
Free alerts the day a new cluster buy is filed, plus the Monday report of the week's biggest insider trades.
Free · unsubscribe anytime · not investment advice · see a sample issue
BLSM insider buying and selling by quarter
Open-market purchases (green, above the line) and sales (red, below), by trade date.
| Quarter | Bought | Purchases | Sold | Sales |
|---|---|---|---|---|
| Q4 2026 | — | 0 | — | 0 |
| Q3 2026 | $25.2M | 7 | — | 0 |
Valuation, profit and volume
Summary
Over the past 12 months, 6 BlossomHill Therapeutics, Inc. insiders reported open-market purchases totaling $25.2M, while 0 insiders reported sales totaling $0. The most recent cluster buy began on Aug 7, 2026, when 6 insiders bought a combined $25.2M.
Insider transactions
Open-market purchases and sales.
| Filed | Insider | Type | Shares | Price | Value | Since | Score |
|---|---|---|---|---|---|---|---|
| Aug 12SEC | Orbimed Capital Gp Viii LlcDirector | Buy | 625,0002,714,279 held (+30%) | $16.00 | $10.0M | +9.3% | — |
| Aug 12SEC | Carl L GordonDirector | Buy | 625,0002,714,279 held (+30%) | $16.00 | $10.0M | +9.3% | — |
| Aug 10SEC | Cormorant Private Healthcare Fund Vi, Lp10% Owner | Buy | 312,5003,614,034 held (+9%) | $16.00 | $5.0M | +9.3% | — |
| Aug 10SEC | John P. SchmidDirector | Buy | 6,000new position | $16.00 | $96K | +9.3% | — |
| Aug 10SEC | Vincent Paul LiptakGeneral Counsel | Buy | 2,500109,212 held (+2%) | $15.80 | $40K | +10.6% | — |
| Aug 10SEC | Vincent Paul LiptakGeneral Counsel | Buy | 2,200111,412 held (+2%) | $16.00 | $35K | +9.3% | — |
| Aug 10SEC | Jason A KeyesCFO | Buy | 700new position | $16.00 | $11K | +9.3% | — |
Insiders at BlossomHill Therapeutics, Inc.
| Insider | Bought | Sold | Last filing | Score |
|---|---|---|---|---|
| Orbimed Capital Gp Viii LlcDirector | $10.0M | — | Aug 12, 2026 | — |
| Carl L GordonDirector | $10.0M | — | Aug 12, 2026 | — |
| Cormorant Private Healthcare Fund Vi, Lp10% Owner | $5.0M | — | Aug 10, 2026 | — |
| John P. SchmidDirector | $96K | — | Aug 10, 2026 | — |
| Vincent Paul LiptakGeneral Counsel | $75K | — | Aug 10, 2026 | — |
| Jason A KeyesCFO | $11K | — | Aug 10, 2026 | — |
BLSM stock: common questions
Are BlossomHill Therapeutics, Inc. insiders buying BLSM stock?
In the past 12 months, 6 insiders reported open-market purchases of BLSM worth $25.2M. The latest was Director Orbimed Capital Gp Viii Llc bought $10.0M of BLSM at $16.00 — first open-market purchase in our records; raises the stake by 30%.
Are BlossomHill Therapeutics, Inc. insiders selling BLSM stock?
0 insiders reported sales worth $0 over the same period.
Where does this data come from?
Every transaction comes from Form 4 filings that insiders must submit to the SEC within two business days of a trade. We pull them from SEC EDGAR every night.
What is BLSM's 52-week range?
Over the past year BLSM has traded between $15.80 and $26.82. It last closed at $17.48 on Oct 9, 2026.